Lingnan Li

715 citations
18 papers · 546 · 1 hit paper · h-index 11

Impact in

    • Spondyloarthritis Studies and Treatments
    • Rheumatoid Arthritis Research and Therapies
    • Psoriasis: Treatment and Pathogenesis

Papers in

    • Natural product bioactivities and synthesis 5
    • Ginseng Biological Effects and Applications 2
    • Spondyloarthritis Studies and Treatments 3
    • Rheumatoid Arthritis Research and Therapies 2

Lingnan Li

17 papers receiving 535 citations

Lingnan Li's Hit Papers

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 2019 · 216 citations
2160+2+4Years since publication50100150200

Peers

Lingnan Li
Comparison fields: 5 of 73
  • Rheumatology 218
  • Immunology 174
  • Hematology 70
  • Pharmacology 36
  • Complementary and alternative medicine 27
Replace Yong‐Liang Chu with:
Yong‐Liang Chu China
Xueping Zhou China
Julio Hilario‐Vargas Peru
Yuhong Yan China
Siddaraju M. Nanjundaiah United States
Chatri Ngamkitidechakul United States
Yilong Zhang China
Sanjeev Roy Germany
Jiutao Qiao China
Yuhun Lu United States
Lingnan Li relative to Yong‐Liang Chu China Yong‐Liang Chu's profile →
Citations per field
00.5×6.7×
Yong‐Liang Chu · 1×
Citations per year

Countries citing papers authored by Lingnan Li

Since Specialization
Citations

This map shows the geographic impact of Lingnan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lingnan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lingnan Li more than expected).

Fields of papers citing papers by Lingnan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lingnan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lingnan Li. The network helps show where Lingnan Li may publish in the future.

Co-authors

The 25 scholars most cited alongside Lingnan Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lingnan Li Line = papers co-authored together Lingnan Li links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
Hit paper breakdown →
2019216
2 202058
3 201854
4 201733
5 201231
6 202030
7 201825
8 201924
9 201918
10 201313
11 202010
12 20199
13 20238
14 20216
15 20196
16 20093
17
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naive Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
20191
18 20241

About Lingnan Li

Lingnan Li is a scholar working on Molecular Biology, Rheumatology, Immunology, Analytical Chemistry and Complementary and alternative medicine, having authored 18 papers that have together received 546 indexed citations. Recurring topics across this work include Natural product bioactivities and synthesis (5 papers), Psoriasis: Treatment and Pathogenesis (3 papers), Spondyloarthritis Studies and Treatments (3 papers), Chromatography in Natural Products (3 papers), Rheumatoid Arthritis Research and Therapies (2 papers), Autoimmune and Inflammatory Disorders Research (2 papers), Ginseng Biological Effects and Applications (2 papers) and Traditional Chinese Medicine Analysis (2 papers). The work is most often cited by research in Rheumatology (218 citations), Immunology (174 citations), Hematology (70 citations), Pharmacology (36 citations) and Complementary and alternative medicine (27 citations). Lingnan Li has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Josef S Smolen, Peter Nash, Sreekumar Pillai, Hasan Tahir, Philip J. Mease, Soyi Liu Leage, Hong Liu‐Seifert, Eswar Krishnan, Philip Helliwell and Frank Behrens. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of Functional Foods, PLoS ONE, Journal of Ethnopharmacology and Chemical Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact